POLYNUCLEOTIDE VACCINATION FOR CANCER-TREATMENT (REVIEW)
Inoculation with pure naked DNA in the form of plasmids can stimulate both antibody and T-cell responses in vivo against plasmid-encoded proteins. Peptide products derived from cytosolic degradation of fragments of tumour-specific proteins, expressed de novo under the transcriptional control of strong mammalian or viral promoter/enhancer signals might gain access to the MHC Class I presentation pathway, mimicking the presentation of viral proteins in infected cells. Presentation as neo-antigens or surrogate antigens in this novel context may be a means of breaking immunological tolerance, and may lead to the generation of tumour-specific immune responses.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Publication date: June 1, 1995
More about this publication?
- The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites